Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Not Just Tech: Invest in Innovation With Healthcare

BY | ETF Database
11:46 am ET 07/09/26 | 13 VIEWS
  • Related Symbols
  • XLV
Traditionally speaking, folks that have looked to tap into innovation in the AI space have done so through tech exposure, particularly with mega-cap names. This is not a surprise, considering the interplay between these companies and AI innovation. However, healthcare also has many opportunities for innovation.Key Takeaways: Tech has had a longstanding role as a means to invest in innovation, but healthcare stocks are also an attractive means of doing so. These stocks can tap into growth from both AI and weight loss drugs, and also provide defensive value. State Street provides low-cost exposure to the healthcare sector through the State Street Health Care Select Sector SPDR ETF (XLV A). However, tech stocks are certainly not the only way for folks to gain access to the growing AI trend. For instance, the healthcare sector offers a particularly compelling route to access growth from artificial intelligence.  The healthcare industry has been able to implement artificial intelligence into its operations in a multitude of ways. Not only does AI help with administrative tasks, but it assists with diagnostics and imaging, virtual nursing, patient monitoring, and more.  AI also plays a crucial role in streamlining the drug discovery process. A high-quality AI model can help run different molecular combinations to expedite how long it takes to locate a viable drug candidate.  See More: Why AI Spending Is Favoring Industrials & Utilities Growth and innovation within the sector is not limited to AI adoption, either. Weight loss medication is becoming increasingly popular, and a recent Gallup poll notes that 11% of U.S. adults are reporting using GLP-1 medicine for weight loss, up 8% from 2024’s numbers.  Best of all, healthcare exposure works as more than a growth play. Healthcare stocks are often relied upon due to their defensive value amid economic downturns. This is due to their inelastic demand — regardless of how the economy is doing, people still need these services to support their well-being.  See More: SPDR Sector ETFs: Tech Leads May RallyWith Healthcare In the Spotlight, Consider XLVThe State Street Health Care Select Sector SPDR ETF (XLV A) can offer low-cost exposure to a variety of different healthcare companies. This fund focuses on investing in healthcare stocks within the S&P 500. Considering how many attractive healthcare companies sit inside the S&P 500, this could be a good opportunity to capitalize on the sector.  Over the long term, XLV’s direct approach to healthcare stocks has given its investors strong long-term performance. As of May 31, 2026, the fund’s NAV has risen 14.66% over the past twelve months.  For more news, information, and analysis, visit our Sector Investing Content Hub.

More Commentary

Defying Rate Pressures: Real Estate ETFs Outpace Broader Market
BY | ETF Database
10:52 am ET 07/09/26 | 14 VIEWS
Electrification Surge Fuels Case for Clean Energy ETF ACES
BY | ETF Database
5:12 am ET 07/09/26 | 36 VIEWS
SK Hynix U.S. IPO Could Boost This ETF
BY | ETF Database
12:48 pm ET 07/09/26 | 6 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.